Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
Applying Osivax’ proprietary oligoDOM® technology platform, OVX836 is designed to target the nucleoprotein (NP), a highly conserved internal antigen.
- Applying Osivax’ proprietary oligoDOM® technology platform, OVX836 is designed to target the nucleoprotein (NP), a highly conserved internal antigen.
- OligoDOM® enables the transformation of the NP into a highly immunogenic antigen to trigger powerful T-cell immune responses.
- Importantly, OVX836 provided an 84% level of protection against PCR-confirmed symptomatic influenza compared to placebo.
- As such, we look forward to advancing OVX836 toward the next stages of clinical development as a truly universal influenza vaccine.”